Skip to search formSkip to main contentSkip to account menu

BTI 322

Known as: BTI-322 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for
2004
2004
The anti‐CD2 monoclonal antibody BTI‐322 generates unresponsiveness by activation‐associated T cell depletion
The antihuman CD2 MoAb BTI‐322 (Lo‐CD2a) effectively inhibits T cell responses in vitro to allogeneic cells, which is followed by… 
2004
2004
A Role for CD2 Antibodies (BTI-322 and its Humanized Form) in the in vivo Elimination of Human T Lymphocytes Infiltrating an Allogeneic Human Skin Graft in SCID Mice: An Fc&ggr; Receptor-Related…
Background. Pilot clinical studies have shown that the rat anti-human-CD2 monoclonal antibody, LoCD2a/BTI-322, can efficiently… 
1999
1999
THE USE OF TACROLIMUS (TAC) AND ANTI-CD2 ANTIBODY Lo-CD2a (BTI-322) IN ADULT LIVER TRANSPLANTATION (LT): PRELIMINARY RESULTS OF A PROSPECTIVE RANDOMIZED STUDY
1998
1998
A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease
BTI-322, a rat monoclonal IgG2b directed against the CD2 antigen on T cells and natural killer (NK) cells, blocks primary and… 
1998
1998
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
BTI-322, a rat monoclonal IgG2b directed against the CD2 antigen on T cells and natural killer (NK) cells, blocks primary and… 
1998
1998
A Phase II Study of BTI-322 , a Monoclonal Anti-CD 2 Antibody , for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease
BTI-322, a rat monoclonal IgG2b directed against the CD2 antigen on T cells and natural killer (NK) cells, blocks primary and… 
1997
1997
BTI-322 for acute rejection after renal transplantation.
1997
1997
BTI-322 for induction therapy after renal transplantation: a randomized study.
1997
1997
Prevention of rejection with BTI-322 after renal transplantation (results at 9 months).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)